QALSODY: the first and only genetically targeted treatment for SOD1-ALS1
Video Player is loading.
Current Time 0:00
/
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time -0:00
1x
Chapters
descriptions off, selected
captions and subtitles off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
QALSODY® (tofersen) is indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. This indication is approved under accelerated approval based on reduction in plasma neurofilament light chain (NfL) observed in patients treated with QALSODY. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s).
